Cargando…

TCR-NK Cells: A Novel Source for Adoptive Immunotherapy of Cancer

Antigen-specific retargeting of cytotoxic lymphocytes against tumor-associated antigens has thus far remained largely dependent on chimeric antigen receptors (CARs) that can be constructed by the fusion of an extracellular targeting domain (classically a single-chain variable fragment from an antibo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karahan, Zeynep Sena, Aras, Mertkaya, Sütlü, Tolga
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Galenos Publishing 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979742/ https://www.ncbi.nlm.nih.gov/pubmed/36719099 http://dx.doi.org/10.4274/tjh.galenos.2022.2022.0534

Ejemplares similares

Trial Watch: Adoptive TCR-Engineered T-Cell Immunotherapy for Acute Myeloid Leukemia
por: Campillo-Davo, Diana, et al.
Publicado: (2021)

New Orders to an Old Soldier: Optimizing NK Cells for Adoptive Immunotherapy in Hematology
por: Gunduz, Mehmet, et al.
Publicado: (2021)

The Advantages and Challenges of Anticancer Dendritic Cell Vaccines and NK Cells in Adoptive Cell Immunotherapy
por: Abakushina, Elena V., et al.
Publicado: (2021)

Toward the next generation of NK cell-based adoptive cancer immunotherapy
por: Ni, Jing, et al.
Publicado: (2013)

TCR-like antibodies in cancer immunotherapy
por: He, Qinghua, et al.
Publicado: (2019)

NK cells specifically TCR-dressed to kill cancer cells
por: Mensali, Nadia, et al.
Publicado: (2019)

Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy
por: Rath, Jan A., et al.
Publicado: (2020)

Optimizing the Procedure to Manufacture Clinical-Grade NK Cells for Adoptive Immunotherapy
por: Fernández, Adrián, et al.
Publicado: (2021)

ErbB2/HER2-specific NK cells for adoptive cancer immunotherapy
por: Zhang, Congcong, et al.
Publicado: (2013)

TCR engineered T cells for solid tumor immunotherapy
por: Zhang, Yikai, et al.
Publicado: (2022)

Development of adoptive immunotherapy with KK‐LC‐1‐specific TCR‐transduced γδT cells against lung cancer cells
por: Ichiki, Yoshinobu, et al.
Publicado: (2020)

NK Cell-Based Immunotherapies in Cancer
por: Shin, Min Hwa, et al.
Publicado: (2020)

NK Cell-Based Immunotherapy in Cancer Metastasis
por: Lorenzo-Herrero, Seila, et al.
Publicado: (2018)

NK Cell-Based Immunotherapy in Colorectal Cancer
por: Della Chiesa, Mariella, et al.
Publicado: (2022)

Molecular Analysis of Elements of Melanoma Insensitivity to TCR-Engineered Adoptive Cell Therapy
por: Jazirehi, Ali R.
Publicado: (2021)

TCR-Engineered, Customized, Antitumor T Cells for Cancer Immunotherapy: Advantages and Limitations
por: Chhabra, Arvind
Publicado: (2011)

ErbB2/Her2-specific NK cells for adoptive immunotherapy of glioblastoma
por: Zhang, Congcong, et al.
Publicado: (2014)

Functional Assessment for Clinical Use of Serum-Free Adapted NK-92 Cells
por: Chrobok, Michael, et al.
Publicado: (2019)

Beyond TCR Signaling: Emerging Functions of Lck in Cancer and Immunotherapy
por: Bommhardt, Ursula, et al.
Publicado: (2019)

The Function of NK Cells in Tumor Metastasis and NK Cell-Based Immunotherapy
por: Yu, Yanlin
Publicado: (2023)

The Advances and Challenges of NK Cell-Based Cancer Immunotherapy
por: Kang, Synat, et al.
Publicado: (2021)

NK Cell Regulation in Cervical Cancer and Strategies for Immunotherapy
por: Gutiérrez-Hoya, Adriana, et al.
Publicado: (2021)

NK Cell-Based Glioblastoma Immunotherapy
por: Golán, Irene, et al.
Publicado: (2018)

Mechanisms of Resistance to NK Cell Immunotherapy
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2020)

Donor selection for adoptive immunotherapy with NK cells in AML patients: Comparison between analysis of lytic NK cell clones and phenotypical identification of alloreactive NK cell repertoire
por: Meazza, Raffaella, et al.
Publicado: (2023)

TCR-T Immunotherapy: The Challenges and Solutions
por: Liu, Yating, et al.
Publicado: (2022)

Adoptive immunotherapy against ovarian cancer
por: Mittica, Gloria, et al.
Publicado: (2016)

Application Of Adoptive Immunotherapy In Ovarian Cancer
por: Yang, Siyu, et al.
Publicado: (2019)

Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges
por: Pang, Zhi, et al.
Publicado: (2023)

Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia
por: Zhou, Weijun, et al.
Publicado: (2022)

NK cell-based tumor immunotherapy
por: Zhang, Hao, et al.
Publicado: (2023)

Adoptive T Cell Immunotherapy for Cancer
por: Perica, Karlo, et al.
Publicado: (2015)

Adoptive T cell therapy: Addressing challenges in cancer immunotherapy
por: Yee, Cassian
Publicado: (2005)

CAR-NK cells: A promising cellular immunotherapy for cancer
por: Xie, Guozhu, et al.
Publicado: (2020)

CAR-NK cells for cancer immunotherapy: from bench to bedside
por: Zhang, Leisheng, et al.
Publicado: (2022)

Optimising NK cell metabolism to increase the efficacy of cancer immunotherapy
por: Choi, Chloe, et al.
Publicado: (2021)

CAR NK-92 cell–mediated depletion of residual TCR(+) cells for ultrapure allogeneic TCR-deleted CAR T-cell products
por: Kath, Jonas, et al.
Publicado: (2023)

Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy
por: Wu, Xinyu, et al.
Publicado: (2022)

Adoptive Cellular Therapy for Multiple Myeloma Using CAR- and TCR-Transgenic T Cells: Response and Resistance
por: Füchsl, Franziska, et al.
Publicado: (2022)

Adoptive Immunotherapy beyond CAR T-Cells
por: Titov, Aleksei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h4o32sqvo3dsss2038cfg170eq